Pailin Biotech (000403): 2024H1 performance exceeds expectations and is optimistic about full-year performance
Pailin Biotech (000403): Blood products market boom continues, company performance exceeds expectations
Pailin Biotech (000403): High performance growth in the first half of the year, and the enabling effects of Shaanxi coal are gradually showing
Morgan Stanley Starts Pacific Shuanglin Bio-pharmacy at Overweight With 37 Yuan Price Target
Pailin Biotech (000403): Performance is in line with expectations, slurry volume reaches an inflection point of growth
Pailin Biotech (000403): Multiple factors drive rapid growth in performance and the scale of pulp harvesting has reached the first tier
Pailin Biotech (000403) 2023 Report 2024 Quarterly Report Review: Pulp harvesting has fully recovered into savings potential for subsequent growth
Pailin Biotech (000403): Pulp harvesting fully recovered to save potential for subsequent growth
Pailin Biotech (000403): Significant increase in pulp collection, profitability is expected to rise steadily
Huayuan Securities released a research report on April 25 stating that Pailin Biotech (000403.SZ) was given a purchase rating. The main reasons for the rating include: 1) the company is one of the leading domestic blood products companies with strong long
China Post Securities released a research report on April 16 stating that Pailin Biotech (000403.SZ) was given a purchase rating. The main reasons for the rating include: 1) due to the decrease in plasma supply in 2022H2, a slight increase in 2023 perform
Pailin Biotech (000403): Balancing stability and growth, the company enters the fast track of development
Pailin Biotech (000403): Baiquan Plasma Station was certified to extract plasma and supply capacity was further improved
Pailin Biotech (000403): Jingbing exports continue to promote the company's long-term steady growth and refuel momentum
Pailin Biotech (000403): Shaanxi's state-owned investment is expected to help the company develop rapidly, highlighting the inflection point in performance
Pailin Biotech (000403) covers the report for the first time: a rapidly rising leading blood products company
Pailin Biotech (000403): Pulp harvesting has resumed significantly and is expected to accelerate significantly in the second half of the year
Pailin Biotech (000403): Performance fluctuations in the third quarter are expected to improve month-on-month in the fourth quarter
Pailin Biotech (000403): Short-term performance is under pressure under the pandemic, profit margins continue to rise
Pailin Biotech (000403): Q2 performance affected by the epidemic, overseas sales performance was relatively outstanding
No Data